FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113848898> ?p ?o ?g. }

• W2113848898 abstract "Abstract Background Drug-drug interactions resulting from the inhibition of an enzymatic process can have serious implications for clinical drug therapy. Quantification of the drugs internal exposure increase upon administration with an inhibitor requires understanding to avoid the drug reaching toxic thresholds. In this study, we aim to predict the effect of the CYP3A4 inhibitors, itraconazole (ITZ) and its primary metabolite, hydroxyitraconazole (OH-ITZ) on the pharmacokinetics of the anesthetic, midazolam (MDZ) and its metabolites, 1' hydroxymidazolam (1OH-MDZ) and 1' hydroxymidazolam glucuronide (1OH-MDZ-Glu) using mechanistic whole body physiologically-based pharmacokinetic simulation models. The model is build on MDZ, 1OH-MDZ and 1OH-MDZ-Glu plasma concentration time data experimentally determined in 19 CYP3A5 genotyped adult male individuals, who received MDZ intravenously in a basal state. The model is then used to predict MDZ, 1OH-MDZ and 1OH-MDZ-Glu concentrations in an CYP3A-inhibited state following ITZ administration. Results For the basal state model, three linked WB-PBPK models (MDZ, 1OH-MDZ, 1OH-MDZ-Glu) for each individual were elimination optimized that resulted in MDZ and metabolite plasma concentration time curves that matched individual observed clinical data. In vivo K m and V max optimized values for MDZ hydroxylation were similar to literature based in vitro measures. With the addition of the ITZ/OH-ITZ model to each individual coupled MDZ + metabolite model, the plasma concentration time curves were predicted to greatly increase the exposure of MDZ as well as to both increase exposure and significantly alter the plasma concentration time curves of the MDZ metabolites in comparison to the basal state curves. As compared to the observed clinical data, the inhibited state curves were generally well described although the simulated concentrations tended to exceed the experimental data between approximately 6 to 12 hours following MDZ administration. This deviations appeared to be greater in the CYP3A5 *1/*1 and CYP3A5 *1/*3 group than in the CYP3A5 *3/*3 group and was potentially the result of assuming that ITZ/OH-ITZ inhibits both CYP3A4 and CYP3A5, whereas in vitro inhibition is due to CYP3A4. Conclusion This study represents the first attempt to dynamically simulate metabolic enzymatic drug-drug interactions via coupled WB-PBPK models. The workflow described herein, basal state optimization followed by inhibition prediction, is novel and will provide a basis for the development of other inhibitor models that can be used to guide, interpret, and potentially replace clinical drug-drug interaction trials." @default.
• W2113848898 created "2016-06-24" @default.
• W2113848898 creator A5019411028 @default.
• W2113848898 creator A5023470192 @default.
• W2113848898 creator A5044550530 @default.
• W2113848898 creator A5061114113 @default.
• W2113848898 creator A5064370332 @default.
• W2113848898 creator A5080644877 @default.
• W2113848898 date "2007-03-26" @default.
• W2113848898 modified "2023-10-08" @default.
• W2113848898 title "Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models" @default.
• W2113848898 cites W1499541462 @default.
• W2113848898 cites W1589451590 @default.
• W2113848898 cites W1929292775 @default.
• W2113848898 cites W1979121500 @default.
• W2113848898 cites W1979150683 @default.
• W2113848898 cites W1987825082 @default.
• W2113848898 cites W1991512646 @default.
• W2113848898 cites W1994629475 @default.
• W2113848898 cites W1999259563 @default.
• W2113848898 cites W2008440205 @default.
• W2113848898 cites W2012293219 @default.
• W2113848898 cites W2016911126 @default.
• W2113848898 cites W2017334752 @default.
• W2113848898 cites W2030475758 @default.
• W2113848898 cites W2031722362 @default.
• W2113848898 cites W2031742675 @default.
• W2113848898 cites W2033290892 @default.
• W2113848898 cites W2042446520 @default.
• W2113848898 cites W2050937868 @default.
• W2113848898 cites W2052006868 @default.
• W2113848898 cites W2052406081 @default.
• W2113848898 cites W2064799851 @default.
• W2113848898 cites W2069193583 @default.
• W2113848898 cites W2076336531 @default.
• W2113848898 cites W2079192244 @default.
• W2113848898 cites W2088904918 @default.
• W2113848898 cites W2105902511 @default.
• W2113848898 cites W2110931244 @default.
• W2113848898 cites W2113547858 @default.
• W2113848898 cites W2115111647 @default.
• W2113848898 cites W2121484553 @default.
• W2113848898 cites W2123282873 @default.
• W2113848898 cites W2138866540 @default.
• W2113848898 cites W2157049173 @default.
• W2113848898 cites W2158747266 @default.
• W2113848898 cites W2160171376 @default.
• W2113848898 cites W2169984670 @default.
• W2113848898 cites W2171012483 @default.
• W2113848898 cites W321311831 @default.
• W2113848898 cites W4253724048 @default.
• W2113848898 cites W4323284006 @default.
• W2113848898 doi "https://doi.org/10.1186/1742-4682-4-13" @default.
• W2113848898 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1853074" @default.
• W2113848898 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17386084" @default.
• W2113848898 hasPublicationYear "2007" @default.
• W2113848898 type Work @default.
• W2113848898 sameAs 2113848898 @default.
• W2113848898 citedByCount "57" @default.
• W2113848898 countsByYear W21138488982012 @default.
• W2113848898 countsByYear W21138488982013 @default.
• W2113848898 countsByYear W21138488982014 @default.
• W2113848898 countsByYear W21138488982015 @default.
• W2113848898 countsByYear W21138488982016 @default.
• W2113848898 countsByYear W21138488982017 @default.
• W2113848898 countsByYear W21138488982018 @default.
• W2113848898 countsByYear W21138488982019 @default.
• W2113848898 countsByYear W21138488982020 @default.
• W2113848898 countsByYear W21138488982021 @default.
• W2113848898 countsByYear W21138488982022 @default.
• W2113848898 countsByYear W21138488982023 @default.
• W2113848898 crossrefType "journal-article" @default.
• W2113848898 hasAuthorship W2113848898A5019411028 @default.
• W2113848898 hasAuthorship W2113848898A5023470192 @default.
• W2113848898 hasAuthorship W2113848898A5044550530 @default.
• W2113848898 hasAuthorship W2113848898A5061114113 @default.
• W2113848898 hasAuthorship W2113848898A5064370332 @default.
• W2113848898 hasAuthorship W2113848898A5080644877 @default.
• W2113848898 hasBestOaLocation W21138488981 @default.
• W2113848898 hasConcept C109650736 @default.
• W2113848898 hasConcept C112705442 @default.
• W2113848898 hasConcept C11824378 @default.
• W2113848898 hasConcept C149151106 @default.
• W2113848898 hasConcept C150903083 @default.
• W2113848898 hasConcept C16005928 @default.
• W2113848898 hasConcept C185592680 @default.
• W2113848898 hasConcept C185867374 @default.
• W2113848898 hasConcept C207001950 @default.
• W2113848898 hasConcept C2776814716 @default.
• W2113848898 hasConcept C2777071850 @default.
• W2113848898 hasConcept C2777477808 @default.
• W2113848898 hasConcept C2778000748 @default.
• W2113848898 hasConcept C2779548794 @default.
• W2113848898 hasConcept C526171541 @default.
• W2113848898 hasConcept C55493867 @default.
• W2113848898 hasConcept C62231903 @default.
• W2113848898 hasConcept C71924100 @default.
• W2113848898 hasConcept C86803240 @default.
• W2113848898 hasConcept C97320921 @default.
• W2113848898 hasConcept C98274493 @default.

• next